As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.
The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.
An obvious feature of autumn that is different from summer is that the temperature drops, the weather is unpredictable, and the temperature difference between morning and night is large, which has become one of the main causes of female biological clock disorder, endocrine disorder and bacterial infection in autumn. In addition, the resistance of the human body decreases relatively in autumn, which is also a time of high recurrence for patients with gynecological diseases.
Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.
Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.
Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!
According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.
Stomach cancer can cause abnormal symptoms in the digestive system, even vomiting blood and black stools, so it should be treated promptly after having stomach cancer
The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.
